iSonea to trial wheeze diagnostic in children

Medical device company iSonea (ASX:ISN) has launched a post-market study of its WheezoMeter monitoring technology in paediatric patients.

The trial will be the first large US study of the device in a paediatric population, and will be conducted across two sights on the US west coast.

The sample group will include patients who are too young to be tested using the traditional spirometry measuring technique, in a bid to determine whether WheezoMeter can fulfil this unmet need.

iSonea's WheezoMeter device uses the company's Acoustic Respiratory Monitoring (ARM) technology and signal processing software to determine the presence, frequency and severity of a wheeze.

In contrast to traditional lung function tests, the device requires no physical exertion and can be used to enable monitoring in real-life conditions.

iSonea changed its name from KarmelSonix in August 2011. The company has a head office in Sydney, a corporate HQ in the US and manufacturing facilities in Israel.

In November last year, iSonea revealed plans to ramp up commercialisation of its ARM products, including WheezoMeter, in the US and other key asthma markets.

The products have already been approved by the Australian TGA, the US FDA and Europe's CE.

iSonea (ASX:ISN) shares closed unchanged on Wednesday at $0.004. The share price has been trending down since September, when it briefly topped $0.020.